TY - JOUR
T1 - 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease
AU - Cantorna, M. T.
AU - Munsick, C.
AU - Bemiss, C.
AU - Mahon, B. D.
PY - 2000
Y1 - 2000
N2 - Anecdotal data suggest that the amount of vitamin D available in the environment either from sunshine exposure or diet may be an important factor affecting the development of inflammatory bowel disease (IBD) in humans. We tested the vitamin D hypothesis in an experimental animal model of IBD. Interleukin (IL)-10 knockout (KO) mice, which spontaneously develop symptoms resembling human IBD, were made vitamin D deficient, vitamin D sufficient or supplemented with active vitamin D (1,25-dihydroxycholecalciferol). Vitamin D-deficient IL-10 KO mice rapidly developed diarrhea and a wasting disease, which induced mortality. In contrast, vitamin D-sufficient 1L-10 KO mice did not develop diarrhea, waste or die. Supplementation with 50 IU of cholecalciferol (5.0 μg/d) or 1,25-dihydroxycholecalciferol (0.005 μg/d) significantly (P < 0.05) ameliorated symptoms of IBD in IL-10 KO mice. 1,25-Dihydroxycholecalciferol treatment (0.2 μg/d) for as little as 2 wk blocked the progression and ameliorated (P < 0.05) symptoms in IL-10 KO mice with already established IBD.
AB - Anecdotal data suggest that the amount of vitamin D available in the environment either from sunshine exposure or diet may be an important factor affecting the development of inflammatory bowel disease (IBD) in humans. We tested the vitamin D hypothesis in an experimental animal model of IBD. Interleukin (IL)-10 knockout (KO) mice, which spontaneously develop symptoms resembling human IBD, were made vitamin D deficient, vitamin D sufficient or supplemented with active vitamin D (1,25-dihydroxycholecalciferol). Vitamin D-deficient IL-10 KO mice rapidly developed diarrhea and a wasting disease, which induced mortality. In contrast, vitamin D-sufficient 1L-10 KO mice did not develop diarrhea, waste or die. Supplementation with 50 IU of cholecalciferol (5.0 μg/d) or 1,25-dihydroxycholecalciferol (0.005 μg/d) significantly (P < 0.05) ameliorated symptoms of IBD in IL-10 KO mice. 1,25-Dihydroxycholecalciferol treatment (0.2 μg/d) for as little as 2 wk blocked the progression and ameliorated (P < 0.05) symptoms in IL-10 KO mice with already established IBD.
UR - http://www.scopus.com/inward/record.url?scp=0033745125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033745125&partnerID=8YFLogxK
U2 - 10.1093/jn/130.11.2648
DO - 10.1093/jn/130.11.2648
M3 - Article
C2 - 11053501
AN - SCOPUS:0033745125
SN - 0022-3166
VL - 130
SP - 2648
EP - 2652
JO - Journal of Nutrition
JF - Journal of Nutrition
IS - 11
ER -